Literature DB >> 8082313

p53 protein detected by immunohistochemical staining is not always mutant.

C MacGeoch1, D M Barnes, J A Newton, S Mohammed, S V Hodgson, M Ng, D T Bishop, N K Spurr.   

Abstract

The expression of the tumour suppressor gene p53 was analyzed in a variety of human solid tumours by immunohistochemistry and direct DNA sequencing. Positive nuclear staining using a panel of anti-p53 antibodies was used to select tumours for further genetic analysis. Using PCR amplification followed by immobilization onto magnetic beads and direct sequencing, we sequenced exons 5-9 of the p53 gene from 9 melanomas, 8 nasopharyngeal carcinomas, 16 sporadic breast carcinomas and 11 patients from familial breast cancer families. No sequence alterations of the p53 gene were detected in either the melanoma or nasopharyngeal tumours and only 19% of the primary breast carcinomas showed a variant band indicative of a mutation. Our results indicate firstly that p53 mutations are not generally involved in the tumour types studied and secondly the data emphasize the disparity encountered when attempting to correlate p53 immunohistochemical positivity with mutations within the p53 gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8082313     DOI: 10.1155/1993/480686

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  8 in total

1.  Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Authors:  M J Pykett; J Landers; D L George
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

2.  Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.

Authors:  C MacGeoch; G Turner; L G Bobrow; D M Barnes; D T Bishop; N K Spurr
Journal:  J Med Genet       Date:  1995-03       Impact factor: 6.318

3.  Immunohistochemical expression of latent membrane protein 1 (LMP1) and p53 in nasopharyngeal carcinoma: Moroccan experience.

Authors:  I Tabyaoui; Z Serhier; S Sahraoui; S Sayd; R Cadi; O M Bennani; A Benider; S Zamiati; Jouti N Tahiri
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

4.  TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.

Authors:  Amber N Hurson; Mustapha Abubakar; Alina M Hamilton; Kathleen Conway; Katherine A Hoadley; Michael I Love; Andrew F Olshan; Charles M Perou; Montserrat Garcia-Closas; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-04       Impact factor: 4.090

5.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region.

Authors:  Alexander Gröbe; Henning Hanken; Ahmed Al-Dam; Georg Cachovan; Ralf Smeets; Antje Krohn; Till Clauditz; Tobias Grob; Ronald Simon; Guido Sauter; Lan Kluwe; Max Heiland; Marco Blessmann
Journal:  Clin Oral Investig       Date:  2013-02-13       Impact factor: 3.573

7.  Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones.

Authors:  K L van Golen; S Risin; A Staroselsky; D Berger; M A Tainsky; S Pathak; J E Price
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

8.  Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma.

Authors:  Hye-Jin Lee; Young-Hoon Kang; Jong-Sil Lee; June-Ho Byun; Uk-Kyu Kim; Si-Jung Jang; Gyu-Jin Rho; Bong-Wook Park
Journal:  BMC Oral Health       Date:  2015-12-01       Impact factor: 2.757

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.